Merus (NASDAQ:MRUS) Receives Consensus Rating of “Buy” from Brokerages

Shares of Merus (NASDAQ:MRUS) have earned an average recommendation of “Buy” from the fourteen ratings firms that are covering the company, MarketBeat.com reports. Twelve research analysts have rated the stock with a buy rating and two have issued a strong buy rating on the company. The average 12 month price target among brokers that have issued ratings on the stock in the last year is $85.45.

Several research firms recently issued reports on MRUS. HC Wainwright reissued a “buy” rating and issued a $85.00 target price on shares of Merus in a research note on Monday. UBS Group began coverage on Merus in a research note on Thursday, October 24th. They issued a “buy” rating and a $72.00 target price on the stock. Needham & Company LLC reissued a “buy” rating and issued a $85.00 target price on shares of Merus in a research note on Monday. Guggenheim raised their target price on Merus from $93.00 to $111.00 and gave the stock a “buy” rating in a research note on Tuesday, October 1st. Finally, The Goldman Sachs Group began coverage on Merus in a research note on Thursday, November 21st. They issued a “buy” rating and a $73.00 target price on the stock.

Institutional Trading of Merus

Hedge funds have recently made changes to their positions in the stock. nVerses Capital LLC boosted its position in shares of Merus by 750.0% in the 3rd quarter. nVerses Capital LLC now owns 1,700 shares of the biotechnology company’s stock worth $85,000 after purchasing an additional 1,500 shares in the last quarter. US Bancorp DE bought a new stake in shares of Merus in the 3rd quarter worth approximately $103,000. Mirae Asset Global Investments Co. Ltd. boosted its position in shares of Merus by 24.7% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,467 shares of the biotechnology company’s stock worth $118,000 after purchasing an additional 489 shares in the last quarter. MML Investors Services LLC bought a new stake in shares of Merus in the 3rd quarter worth approximately $206,000. Finally, Farallon Capital Management LLC bought a new stake in shares of Merus in the 2nd quarter worth approximately $237,000. 96.14% of the stock is owned by institutional investors.

Merus Trading Up 8.2 %

MRUS opened at $48.53 on Tuesday. The company has a market cap of $3.32 billion, a P/E ratio of -12.29 and a beta of 1.12. The business’s 50-day moving average price is $49.93 and its 200-day moving average price is $51.88. Merus has a 12 month low of $22.27 and a 12 month high of $61.61.

Merus (NASDAQ:MRUS) last released its quarterly earnings data on Thursday, October 31st. The biotechnology company reported ($0.95) EPS for the quarter, missing the consensus estimate of ($0.90) by ($0.05). The company had revenue of $11.77 million during the quarter, compared to analysts’ expectations of $9.11 million. Merus had a negative return on equity of 38.89% and a negative net margin of 680.61%. Equities research analysts forecast that Merus will post -3.89 earnings per share for the current fiscal year.

About Merus

Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1.